Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when GPCR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStructure Therapeutics reports 16.3% weight loss in Phase 2, receives FDA Phase 3 clearance
Filed May 7, 2026 · Period ending May 7, 2026 · ~1 min read
Key Changes
-
high
Aleniglipron achieved 16.3% placebo-adjusted weight loss (39 lbs) at 180mg and 16.0% (37 lbs) at 240mg in 44-week Phase 2 ACCESS II study, with no weight loss plateau observed.
Exhibit 99.1 view on EDGAR → -
high
FDA provided positive end-of-Phase 2 feedback with clear Phase 3 guidance; company plans to initiate registrational program for chronic weight management in Q3 2026.
Exhibit 99.1 view on EDGAR → -
high
Company expanded at-the-market equity offering by $150M to up to $400M total capacity and removed aggregate offering cap, providing unlimited flexibility for future capital raises.
Item 8.01 verify on EDGAR → -
high
Cash position of $1.5B as of March 31, 2026 (including $100M upfront license fee for oral GLP-1 patents) expected to fund operations through end of 2028, excluding pre-commercialization costs.
Exhibit 99.1 view on EDGAR → -
medium
Q1 2026 net loss increased to $76.0M from $46.8M year-over-year, driven by higher R&D expenses ($66.5M vs $42.9M) for aleniglipron trials and GLP-1 franchise development.
Exhibit 99.1 view on EDGAR →
Summary
Structure Therapeutics delivered strong Phase 2 obesity data and secured FDA alignment for Phase 3, marking a critical inflection point for its lead oral GLP-1 program. The ACCESS II study showed aleniglipron achieved 16.3% placebo-adjusted weight loss at 44 weeks—the company positions this as best-in-class for oral GLP-1s and potentially competitive with injectables.
With FDA clearance to start Phase 3 registrational trials in Q3 2026, the program advances toward potential commercialization in a massive obesity market. The company simultaneously expanded its capital-raising flexibility, removing the cap on its at-the-market offering and increasing authorized capacity to up to $400M.
With $1.5B cash on hand (bolstered by a $100M licensing payment), management projects runway through end of 2028 for key milestones, though pre-commercialization activities would require additional funding. The Q1 net loss of $76M reflects ramping clinical trial costs as multiple programs advance. Investors should watch for Phase 3 trial design details, enrollment timelines, and any updates on the oral amylin program (Phase 1 data expected second half 2026).
Section-by-Section Diff
Event · Exhibit 99.1
Structure Therapeutics reported Q1 2026 results, positive Phase 2 aleniglipron data (16.3% weight loss), FDA clearance for Phase 3, and $1.5B cash.
Added in current filing · view on EDGAR →
Net loss for the first quarter of 2026 totaled $76.0 million, with non-cash share-based compensation expense of $11.6 million, compared to $46.8 million for the same period in 2025 with non-cash share-based compensation expense of $5.9 million.
Structure Therapeutics reported a net loss of $76.0 million for Q1 2026, up from $46.8 million in Q1 2025. The increase was driven by higher R&D expenses ($66.5M vs $42.9M) for clinical trials and preclinical work on aleniglipron and the GLP-1R franchise, and higher G&A expenses ($22.9M vs $13.4M) to support operational growth. The company received a $100 million upfront license fee for certain oral GLP-1 receptor agonist patents (different from aleniglipron) during the quarter.
Added in current filing · view on EDGAR →
The Company received positive end-of-Phase 2 feedback from the U.S. Food and Drug Administration (FDA) and clear guidance on the Phase 3 program with a starting titration dose of 2.5 mg and the intent to evaluate multiple doses. The Company anticipates initiating the Phase 3 program in Q3 2026.
Structure Therapeutics received positive end-of-Phase 2 feedback from the FDA for aleniglipron, with clear guidance on the Phase 3 program design. The FDA recommended a starting titration dose of 2.5 mg with evaluation of multiple doses. The company plans to initiate the Phase 3 registrational program for chronic weight management in Q3 2026, representing a major advancement toward potential commercialization.
Added in current filing · view on EDGAR →
In December 2025, the Company advanced ACCG-2671 into a Phase 1 clinical study as the industry’s most advanced oral small molecule amylin therapy for the treatment of obesity. ACCG-2671 is being evaluated in an ongoing single ascending dose (SAD) study to measure safety, tolerability, pharmacokinetics, and food-effect of single ascending doses in healthy adult participants with data anticipated in 2H 2026. In addition, the Company expects to initiate a multiple ascending dose (MAD) study in Q3 2026.
The company is advancing ACCG-2671, described as the industry's most advanced oral small molecule amylin therapy for obesity, through Phase 1 development. Initial data from the single ascending dose study is expected in Q3 2026, with a multiple ascending dose study planned to start in Q3 2026. A second oral amylin candidate, ACCG-3535, is expected to enter Phase 1 in Q4 2026. Preclinical data showed combination therapy with semaglutide resulted in superior weight loss compared to either monotherapy.
Event · Item 1.01 — Entry into a Material Definitive Agreement
Structure Therapeutics amended its at-the-market offering agreement to remove the aggregate offering cap on ADS sales.
Added in current filing · verify on EDGAR →
On May 7, 2026, Structure Therapeutics Inc. (the “Company”) amended and restated that certain Sales Agreement dated August 6, 2025 (the “Sales Agreement” and as amended and restated, the “Amended and Restated Sales Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”), relating to the offer and sale of the Company’s American Depositary Shares (“ADSs”), each representing three ordinary shares, $0.0001 par value per ordinary share. The Amended and Restated Sales Agreement modifies the Sales Agreement to remove the aggregate offering amount of ADSs the Company may offer and sell thereunder (the “ATM Shares”).
The company amended its at-the-market equity offering facility with Leerink Partners and Cantor Fitzgerald to eliminate the previous cap on the total dollar amount of $0.0001 ADSs it can sell. This gives the company unlimited flexibility to raise capital through ADS sales under this program, subject to market conditions and regulatory requirements.
Event · Item 2.02 — Results of Operations and Financial Condition
Structure Therapeutics disclosed Q1 2026 financial results and corporate update via press release.
Added in current filing · verify on EDGAR →
On May 7, 2026, the Company issued a press release providing a corporate update and announcing its financial results for the first quarter ended March 31, 2026.
Structure Therapeutics announced its financial results for the first quarter ended March 31, 2026, along with a corporate update. The 8-K itself does not contain the actual financial figures or operational details; those are in the press release furnished as Exhibit 99.1, which is not included in the provided text.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
As of the date of the Prospectus Supplement, the Company previously sold an aggregate of 3,040,000 ATM Shares for gross proceeds of approximately $58,520,000 under the Sales Agreement.
The company disclosed that it had already sold 3,040,000 shares under the prior ATM agreement, generating approximately $58.5 million in gross proceeds. This represents an average price of approximately $19.25 per share. The new $150 million expansion comes on top of the original program, of which roughly $58.5 million has been utilized.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 19, 2026 · How we verify